Imexpharm Corporation (HOSE:IMP)
Vietnam
· Delayed Price · Currency is VND 54,300
+100 (0.18%)
At close: Mar 5, 2026
Imexpharm Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 2,441,085 | 2,205,120 | 1,994,037 | 1,643,707 | 1,266,597 | Upgrade
|
| Revenue Growth (YoY) | 10.70% | 10.59% | 21.31% | 29.77% | -7.51% | Upgrade
|
| Cost of Revenue | 1,278,075 | 1,181,634 | 1,010,064 | 824,152 | 669,657 | Upgrade
|
| Gross Profit | 1,163,010 | 1,023,486 | 983,973 | 819,555 | 596,940 | Upgrade
|
| Selling, General & Admin | 700,575 | 608,328 | 602,926 | 523,055 | 362,868 | Upgrade
|
| Operating Expenses | 700,575 | 608,328 | 602,926 | 523,055 | 362,868 | Upgrade
|
| Operating Income | 462,435 | 415,158 | 381,047 | 296,500 | 234,072 | Upgrade
|
| Interest Expense | -16,501 | -3,489 | -6,036 | -3,795 | -5,496 | Upgrade
|
| Interest & Investment Income | 19,790 | 7,929 | 19,877 | 19,853 | 12,364 | Upgrade
|
| Currency Exchange Gain (Loss) | 1,698 | 2,410 | 2,613 | -2,053 | 3,436 | Upgrade
|
| Other Non Operating Income (Expenses) | -21,248 | -19,555 | -20,221 | -19,448 | -9,413 | Upgrade
|
| EBT Excluding Unusual Items | 446,174 | 402,453 | 377,279 | 291,059 | 234,963 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 1,740 | -6.02 | 345.28 | 3,896 | Upgrade
|
| Gain (Loss) on Sale of Assets | 73.63 | - | - | - | - | Upgrade
|
| Pretax Income | 446,248 | 404,193 | 377,273 | 291,404 | 238,859 | Upgrade
|
| Income Tax Expense | 97,110 | 83,331 | 77,717 | 67,864 | 49,764 | Upgrade
|
| Net Income | 349,138 | 320,862 | 299,556 | 223,540 | 189,095 | Upgrade
|
| Preferred Dividends & Other Adjustments | 44,749 | 23,327 | 21,778 | 39,697 | 15,582 | Upgrade
|
| Net Income to Common | 304,389 | 297,536 | 277,778 | 183,844 | 173,513 | Upgrade
|
| Net Income Growth | 8.81% | 7.11% | 34.01% | 18.22% | -9.83% | Upgrade
|
| Shares Outstanding (Basic) | 154 | 154 | 154 | 154 | 154 | Upgrade
|
| Shares Outstanding (Diluted) | 154 | 154 | 154 | 154 | 154 | Upgrade
|
| Shares Change (YoY) | - | - | -0.00% | -0.00% | 2.92% | Upgrade
|
| EPS (Basic) | 1976.44 | 1931.94 | 1803.65 | 1193.71 | 1126.63 | Upgrade
|
| EPS (Diluted) | 1976.44 | 1931.94 | 1803.65 | 1193.64 | 1126.63 | Upgrade
|
| EPS Growth | 2.30% | 7.11% | 51.11% | 5.95% | -6.15% | Upgrade
|
| Free Cash Flow | 27,292 | 119,497 | -103,064 | 279,250 | 182,024 | Upgrade
|
| Free Cash Flow Per Share | 177.21 | 775.91 | -669.21 | 1813.19 | 1181.89 | Upgrade
|
| Dividend Per Share | - | 500.000 | 454.546 | 432.901 | 649.351 | Upgrade
|
| Dividend Growth | - | 10.00% | 5.00% | -33.33% | - | Upgrade
|
| Gross Margin | 47.64% | 46.41% | 49.35% | 49.86% | 47.13% | Upgrade
|
| Operating Margin | 18.94% | 18.83% | 19.11% | 18.04% | 18.48% | Upgrade
|
| Profit Margin | 12.47% | 13.49% | 13.93% | 11.19% | 13.70% | Upgrade
|
| Free Cash Flow Margin | 1.12% | 5.42% | -5.17% | 16.99% | 14.37% | Upgrade
|
| EBITDA | 565,411 | 519,393 | 463,689 | 356,886 | 294,484 | Upgrade
|
| EBITDA Margin | 23.16% | 23.55% | 23.25% | 21.71% | 23.25% | Upgrade
|
| D&A For EBITDA | 102,976 | 104,235 | 82,642 | 60,386 | 60,412 | Upgrade
|
| EBIT | 462,435 | 415,158 | 381,047 | 296,500 | 234,072 | Upgrade
|
| EBIT Margin | 18.94% | 18.83% | 19.11% | 18.04% | 18.48% | Upgrade
|
| Effective Tax Rate | 21.76% | 20.62% | 20.60% | 23.29% | 20.83% | Upgrade
|
| Revenue as Reported | 2,441,085 | 2,205,120 | 1,994,037 | 1,643,707 | 1,266,597 | Upgrade
|
| Advertising Expenses | 161,446 | 170,332 | 175,099 | 123,665 | 110,468 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.